Curr Probl Cardiol. 2021 Mar;46(3):100554. doi: 10.1016/j.cpcardiol.2020.100554. Epub 2020 Feb 14.
During the annual meeting in Paris, the European Society of Cardiology released the new guidelines for the diagnosis and management of chronic coronary syndromes that will replace the 2013 guidelines on stable coronary artery disease. We intend to provide a brief commentary on what, in our opinion, is good and what is not as good. Our careful analysis shows that the 2019 guidelines contain a number of positive innovations, including a new definition, a central role of non-invasive testing for myocardial ischaemia, the most contemporary prevalence of the disease, the fact that medical therapy remains paramount despite the important advances in revascularisation and many other good issues as well as some limitations. The section on medical therapy of chronic coronary syndromes patients shows some inconsistency between text and the suggested scheme as well as contradictions with recommendations of regulatory agencies. It is not immediate to appreciate what is good and what is not so good in guidelines, which are often read in a hurry. We have provided a short commentary for the readers who usually concentrate more on the figures and flowcharts rather than on the text.
在巴黎举行的年会上，欧洲心脏病学会发布了新的慢性冠状动脉综合征诊断和管理指南，该指南将取代 2013 年稳定型冠状动脉疾病指南。我们打算简要评论一下我们认为好的和不好的方面。我们仔细分析后发现，2019 年指南包含了一些积极的创新，包括一个新的定义、非侵入性心肌缺血检测的核心作用、该疾病的最新流行情况、尽管血运重建术取得了重要进展，但药物治疗仍然至关重要，以及许多其他好的方面和一些局限性。慢性冠状动脉综合征患者的药物治疗部分显示出文本和建议方案之间存在一些不一致，以及与监管机构建议的矛盾。指南通常是匆匆阅读的，因此要立即了解哪些方面好，哪些方面不好并不容易。我们为那些通常更关注图表和流程图而不是文本的读者提供了简短的评论。
